6-Bromo-4-[1-[[6-[(4,4-dimethyl-1-piperidinyl)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-1H-1,2,3-triazol-4-yl]-1H-indazole manufacturers
- STM3006
-
- $88.00
-
2026-06-09
- CAS:2499664-52-5
- Purity: 97.28%
- Supply Ability: 10g
|
| | 6-Bromo-4-[1-[[6-[(4,4-dimethyl-1-piperidinyl)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-1H-1,2,3-triazol-4-yl]-1H-indazole Basic information |
| Product Name: | 6-Bromo-4-[1-[[6-[(4,4-dimethyl-1-piperidinyl)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-1H-1,2,3-triazol-4-yl]-1H-indazole | | Synonyms: | 6-Bromo-4-[1-[[6-[(4,4-dimethyl-1-piperidinyl)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-1H-1,2,3-triazol-4-yl]-1H-indazole;6-Bromo-4-(1-((6-((4,4-dimethylpiperidin-1-yl)methyl)imidazo[1,2-a]pyridin-2-yl)methyl)-1H-1,2,3-triazol-4-yl)-1H-indazole | | CAS: | 2499664-52-5 | | MF: | C25H27BrN8 | | MW: | 519.44 | | EINECS: | | | Product Categories: | | | Mol File: | 2499664-52-5.mol | ![6-Bromo-4-[1-[[6-[(4,4-dimethyl-1-piperidinyl)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-1H-1,2,3-triazol-4-yl]-1H-indazole Structure](CAS/20210305/GIF/2499664-52-5.gif) |
| | 6-Bromo-4-[1-[[6-[(4,4-dimethyl-1-piperidinyl)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-1H-1,2,3-triazol-4-yl]-1H-indazole Chemical Properties |
| density | 1.54±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | | pka | 11.05±0.40(Predicted) | | form | Solid | | color | Light yellow to brown |
| | 6-Bromo-4-[1-[[6-[(4,4-dimethyl-1-piperidinyl)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-1H-1,2,3-triazol-4-yl]-1H-indazole Usage And Synthesis |
| Uses | STM3006 is a highly potent, selective, and orally active inhibitor of METTL3 (IC50: 5 nM). STM3006 can reduce the m6A level, promote the formation of dsRNA, trigger a cell-intrinsic interferon response, and enhance the killing effect of T cells on tumors. STM3006 has anti-tumor activity, and its combination with anti-PD-1 immunotherapy yields better results[1][2]. | | References | [1] Andrew A Guirguis, et al. Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity.Cancer Discov. 2023 Oct 5;13(10):2228-2247. DOI:10.1158/2159-8290.CD-23-0007 [2] Brichkina A, et al. Methyltransferase-like 3 (METTL3) inhibition potentiates anti-tumor immunity: a novel strategy for improving anti-PD1 therapy. Signal Transduct Target Ther. 2023 Dec 11;8(1):448. DOI:10.1038/s41392-023-01696-x |
| | 6-Bromo-4-[1-[[6-[(4,4-dimethyl-1-piperidinyl)methyl]imidazo[1,2-a]pyridin-2-yl]methyl]-1H-1,2,3-triazol-4-yl]-1H-indazole Preparation Products And Raw materials |
|